Wat is de prijs voor Metagenomi, Inc. Common Stock (MGX)

Het prijs van Metagenomi, Inc. Common Stock (MGX) is $1.21

Wat is de marktkapitalisatie voor Metagenomi, Inc. Common Stock (MGX)

Marktkapitalisatie voorMetagenomi, Inc. Common Stock (MGX) is $45.55M

Metagenomi, Inc. Common Stock (MGX) K/O-verhouding

Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.

Jaar	P/S-ratio	Wijzigen
Niet genoeg gegevens voor de verstrekte datums.

Jaar

P/S-ratio

Wijzigen

Niet genoeg gegevens voor de verstrekte datums.

Bedrijf	P/S-ratio	Verschil in P/S-ratio	Land
Vertex Pharmaceuticals Incorporated VRTX.US	10.17	-	US
Argenx SE ARGX.US	10.13	-	NL
CSL Limited CSL.AX	2.95	-	AU
Lonza Group AG LONN.SW	-	-	CH
Moderna, Inc. MRNA.US	11.28	-	US

Bedrijf

P/S-ratio

Verschil in P/S-ratio

Land